Screener
Theravance Biopharma TBPH Free cash flow
Discontinued — last reported Q4 '25
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Theravance Biopharma’s reported figures.
Plus components not separately reported this period.
The source filing: Theravance Biopharma’s 10-K, filed March 23, 2026. Open the filing →
- Filed
- Mar 23, 2026, 8:46 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001104659-26-033077
FAQ
- What is Theravance Biopharma's free cash flow?
- Theravance Biopharma (TBPH) reported free cash flow of $59.62M in Q4 2025.
- How has Theravance Biopharma's free cash flow changed year-over-year?
- Theravance Biopharma's free cash flow increased by 5560.1% year-over-year, from -$1.09M to $59.62M.
- What is the long-term trend for Theravance Biopharma's free cash flow?
- Over 4 years (2021 to 2025), Theravance Biopharma's free cash flow has grown at a 3.1% compound annual growth rate (CAGR), from -$211.26M to $238.5M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Theravance Biopharma's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude